BK vs RXRX · P/E 17, rev $20.08B vs rev $58.8M
The Bank of New York Mellon Corporation (BK) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
BK currently screens at market cap $94.14B and trailing P/E 17.0. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the BK and RXRX stock pages for the full models.
Not investment advice.